Testing effectiveness (Phase 2)Ended earlyNCT03968419
What this trial is testing
This Study Will Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in Combination as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC.
Who this might be right for
Non-small Cell Lung Cancer
Novartis Pharmaceuticals 88